• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝硬化伴难治性腹水患者托伐普坦的血浆浓度和疗效。

Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites.

机构信息

Department of Gastroenterology, Juntendo University Nerima Hospital, Tokyo, Japan.

Department of Gastroenterology, Juntendo University Nerima Hospital, Tokyo, Japan.

出版信息

J Pharmacol Sci. 2019 Apr;139(4):373-376. doi: 10.1016/j.jphs.2019.01.015. Epub 2019 Feb 27.

DOI:10.1016/j.jphs.2019.01.015
PMID:30857764
Abstract

To investigate the relationship between the exposure and efficacy of tolvaptan, we measured pharmacokinetics of total drug at 7 days after repeated doses of 3.75 mg/day tolvaptan in 16 patients with hepatic edema. Nine patients (56.3%) were responders, which were defined as those with body weight reduction of >1.5 kg/week. Serum albumin levels were significantly lower in responders than in non-responders (P = 0.031). However, the pharmacokinetics varied greatly among individuals and was not relevant to the clinical response.

摘要

为了研究托伐普坦的暴露量与疗效之间的关系,我们在 16 例肝性水肿患者中测量了重复给予托伐普坦 3.75mg/天 7 天后的总药物药代动力学。9 例患者(56.3%)为应答者,即每周体重减轻>1.5kg 的患者。应答者的血清白蛋白水平明显低于无应答者(P=0.031)。然而,药代动力学在个体之间差异很大,与临床反应无关。

相似文献

1
Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites.肝硬化伴难治性腹水患者托伐普坦的血浆浓度和疗效。
J Pharmacol Sci. 2019 Apr;139(4):373-376. doi: 10.1016/j.jphs.2019.01.015. Epub 2019 Feb 27.
2
Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).托伐普坦治疗肝硬化伴肝性水肿患者的真实世界疗效和安全性:一项上市后监测研究(START 研究)结果。
J Gastroenterol. 2020 Aug;55(8):800-810. doi: 10.1007/s00535-020-01691-x. Epub 2020 May 9.
3
Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites.肾功能受损可能不会降低托伐普坦治疗肝硬化难治性腹水患者的疗效。
Clin Drug Investig. 2019 Jan;39(1):45-54. doi: 10.1007/s40261-018-0714-5.
4
Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.对托伐普坦治疗有阳性反应将是肝硬化腹水患者的一个良好预后因素。
Dig Dis. 2019;37(3):239-246. doi: 10.1159/000494438. Epub 2019 Jan 9.
5
Long-term administration of Tolvaptan to patients with decompensated cirrhosis.托伐普坦治疗失代偿期肝硬化患者的长期疗效。
Int J Med Sci. 2020 Mar 15;17(7):874-880. doi: 10.7150/ijms.41454. eCollection 2020.
6
Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.托伐普坦对晚期肝硬化患者难治性腹水的生存获益
Dig Dis. 2018;36(4):314-321. doi: 10.1159/000489258. Epub 2018 May 31.
7
Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.托伐普坦对监测生物电阻抗定义的肝硬化腹水患者液体状态的临床意义:一项观察性研究。
BMC Gastroenterol. 2020 Mar 5;20(1):53. doi: 10.1186/s12876-020-01205-2.
8
Tolvaptan for the treatment of liver cirrhosis oedema.托伐普坦用于治疗肝硬化水肿。
Expert Rev Gastroenterol Hepatol. 2014 Jul;8(5):461-70. doi: 10.1586/17474124.2014.903797. Epub 2014 Mar 29.
9
Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.托伐普坦治疗肝硬化患者顽固性腹水的临床疗效
World J Gastroenterol. 2014 Aug 28;20(32):11400-5. doi: 10.3748/wjg.v20.i32.11400.
10
Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.难治性腹水的管理可减轻失代偿期肝硬化患者的肌肉减少症并改善其生存率。
J Gastroenterol. 2020 Feb;55(2):217-226. doi: 10.1007/s00535-019-01623-4. Epub 2019 Sep 4.

引用本文的文献

1
Total body fluid is the factor that affects the pharmacokinetics of tolvaptan, and its efficacy, in acute worsening heart failure patients.总体液是影响托伐普坦在急性恶化心力衰竭患者中药代动力学和疗效的因素。
Pharmacol Res Perspect. 2023 Jun;11(3):e01088. doi: 10.1002/prp2.1088.
2
HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan.HEP-Net关于在巴基斯坦资源有限环境下失代偿期肝硬化患者腹水及其并发症管理的意见。
Pak J Med Sci. 2020 Jul-Aug;36(5):1117-1132. doi: 10.12669/pjms.36.5.2407.